US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor agonist
pharma · refractory hypotension in distributive shock
PAION Pharma
PAION Pharma GmbH
PAION Pharma drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Aachen, DE HQ
2024 Founded
30 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Aachen, DE
- Founded
- 2024
- Employees
- 30
- Programs
- 1
- Drugs
- 6
- Patents
- 0
PAION Pharma pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
PAION Pharma drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to PAION Pharma in public FDA and regional records.
-
Development asset linked to PAION Pharma in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to PAION Pharma in public FDA and regional records.
-
Development asset linked to PAION Pharma in public FDA and regional records.